Cancer

November 2, 2017

Liquid biopsies help reveal lung cancer mutations

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC).

By VUMC News and Communications
(iStock)
October 26, 2017

Study to test combination therapy for breast cancer

Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

By VUMC News and Communications
October 25, 2017

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

By VUMC News and Communications
October 18, 2017

Calcium intake and colorectal cancer

Calcium intake appears to protect against colorectal cancer in individuals with certain gene variants, Vanderbilt researchers have discovered.

By Leigh MacMillan
October 17, 2017

Researchers find novel mechanism of resistance to anti-cancer drugs

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.

By Leigh MacMillan
October 5, 2017

Predators’ fund powers fight against childhood cancer

Nashville Predators goaltender Pekka Rinne, Predators executive leaders, executives from Tri Star Energy (Twice Daily) and team mascot Gnash recently presented the proceeds of the team’s 365 Pediatric Cancer Fund to Monroe Carell Jr. Children’s Hospital at Vanderbilt.

By Christina Echegaray
October 4, 2017

Boosting sarcoma cell death

A compound identified at Vanderbilt represents a new lead for treating rare, aggressive childhood cancers called Ewing sarcomas.
By Leigh MacMillan
September 18, 2017

New cutting-edge treatment for type of pediatric leukemia offered at Monroe Carell Jr. Children’s Hospital at Vanderbilt 

By Christina Echegaray
August 31, 2017

Pancreatic cancer development

Elevated levels of the factor G-CSF appear to promote the development of aggressive pancreatic cancer, suggesting a new therapeutic approach for this devastating disease.
By Leigh MacMillan
August 24, 2017

Hyundai Hope on Wheels award boosts pediatric cancer research

Adam Esbenshade, M.D., MSCI, assistant professor of Pediatrics in the Division of Pediatric Hematology/Oncology, has been awarded a $50,000 Hyundai Hope on Wheels Impact Award. Esbenshade plans to use data to create a risk prediction model to predict blood stream infections in pediatric cancer patients.
By Christina Echegaray
August 21, 2017

Fatty acids and adenoma risk

Vanderbilt researchers have found that red blood cell membrane fatty acid content is associated with risk of having colorectal adenomas, with omega-6 fatty acids increasing and omega-3 fatty acids decreasing risk.
By Leigh MacMillan
August 17, 2017

Kidney cancer patient, survivor event set for Sept. 9

Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898.
By VUMC News and Communications
August 9, 2017

Breast Cancer Genomic Profiling Reveals Clues to Treatment Resistance

Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.
By Bill Snyder